A Study of Ramucirumab (IMC-1121B) in Participants With Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Metastatic Breast Cancer
Interventions: BIOLOGICAL: Ramucirumab|DRUG: Docetaxel
Sponsor: Eli Lilly and Company